| 甲状腺激素与非酒精性脂肪性肝病研究进展 |
| |
| 引用本文： | 陈怡,朱友,周希乔.甲状腺激素与非酒精性脂肪性肝病研究进展[J].实用肝脏病杂志,2023,26(1):145-148. |
| |
| 作者姓名： | 陈怡 朱友 周希乔 |
| |
| 作者单位： | 210000 南京市 南京医科大学第一附属医院消化科(周希乔,陈怡,朱友);南京中医药大学附属医院内分泌科(周希乔) |
| |
| 基金项目： | *国家自然科学基金资助项目(编号:81570522);江苏省中医院医学发展医疗救助基金资助项目(编号:kgr0254) |
| |
| 摘 要： | 非酒精性脂肪性肝病(NAFLD)是肝硬化、肝癌和肝移植的重要原因。全球成年人患病率约为25%,且呈现上升趋势。大量的研究表明甲状腺激素(TH)在肝脏脂质代谢和胰岛素抵抗过程中起着重要的作用，甲状腺激素受体激动剂有望成为治疗NAFLD的新型药物。本文就甲状腺激素与NAFLD的研究进展进行了综述。
|
| 关 键 词： | 非酒精性脂肪性肝病 代谢相关脂肪性肝病 甲状腺激素 |
| 收稿时间： | 2021-09-13 |
Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease |
| |
| Chen Yi,Zhu You,Zhou Xiqiao.Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease[J].Journal of Clinical Hepatology,2023,26(1):145-148. |
| |
| Authors: | Chen Yi Zhu You Zhou Xiqiao |
| |
| Institution: | Department of Gastroenterology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210000,Jiangsu Province, China |
| |
| Abstract: | The nonalcoholic fatty liver disease (NAFLD) is considered to be the metabolic disorders in liver and is closely related to obesity, insulin resistance (IR), type 2 diabetes mellitus (T2DM) and hyperlipemia, etc. The prevalence of NAFLD among adults worldwide is about 25% and it is to believe increasing year by year. The NAFLD is an important causes of liver cirrhosis, liver cancer and liver transplantation. A large number of studies have shown that thyroid hormone (THs) plays an important role in hepatic lipid metabolism and IR, and the thyroid hormone receptor agonists are expected to become new medicines for the treatment of patients with NAFLD. In this review, we mainly discuss the progress of THs in patients with NAFLD. |
| |
| Keywords: | Nonalcoholic fatty liver disease Metabolic-associated fatty liver diseases Thyroid hormone |
|
| 点击此处可从《实用肝脏病杂志》浏览原始摘要信息 |
| 点击此处可从《实用肝脏病杂志》下载免费的PDF全文 |
